Form 8-K - Current report:
SEC Accession No. 0001193125-25-321738
Filing Date
2025-12-17
Accepted
2025-12-17 08:00:18
Documents
14
Period of Report
2025-12-16
Items
Item 3.02: Unregistered Sales of Equity Securities
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d42051d8k.htm   iXBRL 8-K 31211
2 EX-3.1 d42051dex31.htm EX-3.1 76523
3 EX-10.1 d42051dex101.htm EX-10.1 101918
  Complete submission text file 0001193125-25-321738.txt   376248

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA lrmr-20251216.xsd EX-101.SCH 2855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE lrmr-20251216_lab.xml EX-101.LAB 18738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lrmr-20251216_pre.xml EX-101.PRE 11710
16 EXTRACTED XBRL INSTANCE DOCUMENT d42051d8k_htm.xml XML 3853
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 251577277
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)